Business Context and Reporting Period
This Form 6-K is a transaction notification filed by GlaxoSmithKline plc (GSK) for the period ending August 10, 2016. The filing discloses share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) under the Company's ShareReward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It strictly reports specific equity transactions.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.7975 per share.
- Transaction Date: August 9, 2016.
- Exchange: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely details routine share acquisitions by senior executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity.
Important Facts for Investors
- Transaction Type: All reported transactions were acquisitions of ordinary shares under the ShareReward Plan, consisting of partnership shares and matching shares.
- Participants: Transactions were executed by 11 senior executives, including CEO Sir Andrew Witty, CFO Mr S Dingemans, and President of Global Pharmaceuticals Mr S A Hussain.
- Volume: Individual transaction volumes were minimal, ranging from 14 to 16 shares per executive.
- Valuation: The total value per executive ranged approximately from £235 to £269 based on the reported price of £16.7975.